US2011200593A1PendingUtilityA1

Combination Therapy for the Treatment of Ocular Neovascular Disorders

55
Assignee: OPHTHOTECH CORPPriority: Aug 27, 2003Filed: Jan 10, 2011Published: Aug 18, 2011
Est. expiryAug 27, 2023(expired)· nominal 20-yr term from priority
Inventors:David ShimaPerry CaliasAnthony P. Adamis
A61P 43/00A61P 9/00A61P 9/10A61P 27/06A61P 29/00A61P 27/02A61P 17/06A61P 19/02A61K 45/06A61K 39/3955A61K 2039/505A61K 31/7088A61K 31/506C12N 15/1136A61K 39/395A61K 31/52A61K 31/00C12N 15/11A61K 31/519A61K 38/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A method for treating an ocular neovascular disorder, comprising administering to a mammal in need thereof:
 (a) a PDGF antagonist, wherein the PDGF antagonist is a pegylated aptamer having the sequence of SEQ ID NO: 23; and   (b) a VEGF antagonist, wherein the VEGF antagonist is a humanized anti-VEGF antibody having a light chain variable domain comprising the sequence of SEQ ID NO: 27 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26,   wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other, and wherein the PDGF antagonist and the VEGF antagonist are administered in an amount effective to treat the ocular neovascular disorder in the mammal, and   wherein the ocular neovascular disorder is age-related macular degeneration (AMD).   
     
     
         17 . The method of  claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 10 days of each other. 
     
     
         18 . The method of  claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 5 days of each other. 
     
     
         19 . The method of  claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered within 24 hours of each other. 
     
     
         20 . The method of  claim 16 , wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously. 
     
     
         21 . The method of  claim 16 , wherein the PDGF antagonist and VEGF antagonist are administered separately in individual dosage amounts. 
     
     
         22 . The method of  claim 16 , wherein the PDGF antagonist and VEGF antagonist are administered together in the same composition. 
     
     
         23 . The method of  claim 16 , wherein the age-related macular degeneration is wet-type AMD.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.